Comment on Santema et al. Hyperbaric Oxygen Therapy in the Treatment of Ischemic Lower-Extremity Ulcers in Patients With Diabetes: Results of the DAMO2CLES Multicenter Randomized Clinical Trial. Diabetes Care 2018;41:112–119

Mutluoğlu, Mesut

doi:10.2337/dc17-2303

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, hyperbaric oxygen enhances wound healing in diabetes by promoting fibroblast proliferation and endothelial cell angiogenesis (Huang et al, 2020). In the past 20 years, many clinical trials have proved that HBOT can promote the healing of diabetes wounds (Mutluoglu, 2018). HBOT is to treat patients with 100% oxygen above atmospheric pressure.…”

Section: Hyperbaric Oxygen Therapymentioning

confidence: 99%

Effect of composite biodegradable biomaterials on wound healing in diabetes

Ren

Guo²,

Yang³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The repair of diabetic wounds has always been a job that doctors could not tackle quickly in plastic surgery. To solve this problem, it has become an important direction to use biocompatible biodegradable biomaterials as scaffolds or dressing loaded with a variety of active substances or cells, to construct a wound repair system integrating materials, cells, and growth factors. In terms of wound healing, composite biodegradable biomaterials show strong biocompatibility and the ability to promote wound healing. This review describes the multifaceted integration of biomaterials with drugs, stem cells, and active agents. In wounds, stem cells and their secreted exosomes regulate immune responses and inflammation. They promote angiogenesis, accelerate skin cell proliferation and re-epithelialization, and regulate collagen remodeling that inhibits scar hyperplasia. In the process of continuous combination with new materials, a series of materials that can be well matched with active ingredients such as cells or drugs are derived for precise delivery and controlled release of drugs. The ultimate goal of material development is clinical transformation. At present, the types of materials for clinical application are still relatively single, and the bottleneck is that the functions of emerging materials have not yet reached a stable and effective degree. The development of biomaterials that can be further translated into clinical practice will become the focus of research.

show abstract